FTDZX — Franklin Biotechnology Discovery Fund
Data updated: 2026-07-10
FTDZX — Franklin Biotechnology Discovery Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $1.04B AUM · 0.77% expense ratio · 65.4% 1-yr return. From SEC regulatory filings.
FTDZX Fund Overview
FTDZX — Franklin Biotechnology Discovery Fund is a US mutual fund managed by Franklin Strategic Series, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Franklin Strategic Series
- Category: United States Health Care Equity
- Assets under management: $1.04B
- 1-year return: 65.4%
- Ticker: FTDZX
- SEC CIK: 0000872625
- SEC series ID: S000006882
- Share class ID: C000081539
FTDZX Holdings
Top 10 holdings of Franklin Biotechnology Discovery Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Jazz Pharmaceuticals plc | 5.55% |
| Amgen, Inc. | 4.75% |
| Gilead Sciences, Inc. | 4.66% |
| Regeneron Pharmaceuticals, Inc. | 4.16% |
| Vertex Pharmaceuticals, Inc. | 4.02% |
| Argenx SE | 3.69% |
| Franklin Institutional U.S. Government Money Market Fund | 3.05% |
| Franklin Institutional U.S. Government Money Market Fund | 2.96% |
| Ascendis Pharma A/S | 2.87% |
| Insmed, Inc. | 2.82% |
FTDZX Portfolio Allocation
Asset-class allocation of Franklin Biotechnology Discovery Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.7% |
| Cash & Equivalents | 6.0% |
| Other | 0.5% |
FTDZX Performance
Total returns for FTDZX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.7% |
| 1 year | 65.4% |
| 3 years (annualised) | 23.5% |
| 5 years (annualised) | 8.4% |
FTDZX Risk Information
Risk metrics for FTDZX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 19.4%
FTDZX Costs and Fees
FTDZX costs about $77 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.77%
- Gross expense ratio: 0.78%
- Portfolio turnover: 22%
- Brokerage commissions: 8.31 bps of average net assets (SEC N-CEN)
FTDZX Cashflows
Over the 12 months to 2026-04, Franklin Biotechnology Discovery Fund had net outflows of $463.48K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$5.06M |
| 2026-03 | −$7.95M |
| 2026-02 | −$13.78M |
| 2026-01 | −$7.25M |
| 2025-12 | $81.00M |
| 2025-11 | $2.90M |
FTDZX Debt Constituents
No individual debt constituents are reported in Franklin Biotechnology Discovery Fund's latest SEC N-PORT filing.
FTDZX Prospectus and SEC Filings
Official Franklin Biotechnology Discovery Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.